Page xxxviii

References

1) References; Antioxidant Intervention; Fowkes

Anneren G and Edman B, Down syndrome--a gene dosage disease caused by trisomy of genes within a small segment of the long arm of chromosome 21, exemplified by the study of effects from the superoxide type-1 (SOD-1) gene. Apmis Suppl 40: 71-9, 1993.

Antila E, Norberg U-R, Syvaoja E-L and Wetermarck T. Selenium therapy in Down's Syndrome (DS): a theory and a clinical trial. In: Antioxidants in Therapy and Preventative Medicine, pp. 183-86, Plenum Press, New York, 1990.

Daumer-Haus C, Schuffenhauer S, Walther JU, Schipper RD, Porstmann T and Korenberg JR. Tetrasomy 21 pter-->q22.1 and Down's syndrome: molecular definition of the region. American Journal of Medical Genetics 53(4): 359-65, 1 December 1994.

Epstein CJ. Models for Down's syndrome: Chromosome 21-specific genes in mice. Prog Clin Biol Res 360: 215-32, 1990.

MacLeod K. Personal communication, Down's Syndrome Conference, Los Angeles, 24 February 1996.

2) References; Nutritional Intervention in Down Syndrome; Fowkes

Anneren G. and Edman B, Down syndrome -- a gene dosage disease caused by trisomy of genes within a small segment of the long arm of chromosome 21, exemplified by the study of effects from the superoxide type-1 (SOD- 1) gene. AMPIS Suppl 40: 71-9, 1993.

Antila E., Norberg U-R, Syvaoja E-L and Wetermarck T. Selenium therapy in Downs Syndrome (DS): a theory and a clinical trial. In: Antioxidants in Therapy and Preventative Medicine, pp. 183-86, Plenum Press, New York, 1990.

Chadefaux B., Rethor MO, Raoul O, Ceballos I, Poissonnier M, Gilgenkrantx S and Allard D. Cystathionine beta synthase: Gene dosage effect in trisomy 21. Biochem Biophys Res Commun 128: 1-10, 1985.

Daumer-Haas C, Schuffenhauer S, Walther JU, Schipper RD, Porstmann T and Korenberg JR. Tetrasomy of 21 pter--q22.1 and Down syndrome: molecular definition of the region. Amer J Med Genetics Supplement 53(4): 359-65, 1 December 1994.

Epstein CJ. Models for Downs syndrome: Chromosome 21-specific genes in mice. Prog Clin Biol Res 360: 215-32, 1990.

Licastro F., Mocchegiani E, Zannotti M, Arena G and Masi M. Zinc affects the metabolism of thyroid hormones in children with Down's syndrome: normalization of thyroid stimulating hormone and of reversal triiodothyronine plasmic levels by dietary zinc supplementation. International Journal of Neuroscience 65(1-4): 259-68, Jul-Aug 1992. "Before zinc supplementation, plasmic levels of zinc and thymulin, a zinc dependent thymic hormone, were significantly decreased in DS children. After four months of dietary supplementation with zinc sulphate, a normalization of plasma zinc, thymulin and TSH levels was observed. Plasmic levels of rT3 significantly increased, and after zinc treatment no difference was detectable between DS children and normal children. Clinical evaluation of the health status of DS children showed that zinc supplementation decreased the incidence of infectious diseases and improved school attendance."

Murphy M, lnsoft RM, Pike-Nobile L, Derbin KS, Epstein LB. Overexpression of LFA-1 and ICAM-1 in Down syndrome thymus. Implications for abnormal thymocyte maturation. Journal of Immunology 150(12): 5696-703, 15 June 1993. "Given our recent observation that DS thymuses overexpress mRNA for

Page xxxix

IFN-gamma and TNF...." TNF induces indoleamine-2,3-dioxygenase (IDO), the peripheral enzyme which catabolizes tryptophan in response to immune activation.

Napolitano G, Palka G, Grimaldi S, Giuliani C, Laglia G, Calabreese G, Satta MA, Neri G and Monaco F. Growth delay in Downs syndrome and zinc sulphate supplementation. Amer J Med Genetics Supplement 7: 63, 1990.

Peters M. Personal communication, Down's Syndrome Parent Conference, San Diego, 1995.

Stabile A., Pesaresi MA, Stabile AM, Pastore M, Sopo SM, Ricci R, Celestini E and Segni G. Immunodeficiency and plasma zinc levels in children with Down's syndrome: a long-term follow-up of oral zinc supplementation. Clinical Immunology & Immunopathology 58(2): 207-16, February 1991. "63.2% of DS children had plasma Zn levels below 0.7 mcg/dl"-- "DS children showed significantly lower proliferative response to phytohemagglutinin" -- "A significant increase in DNA synthesis was obtained after oral administration of zinc sulfate (20 mg/kg/day), for 2 months)" -- "The lumphocyte response to PHA appeared to be normal in all patients up to six months after the end of zinc supplementation and it became low in half of the patients 22 months after therapy."

3) References; TNI in the Treatment of Children/Adults DS; Leichtman

Declining mortality from Down syndrome--No cause for complacency. Lancet 1990; 335:888-889.

Abalan F. (1984). Alzheimer's disease and malnutrition: a new etiological hypothesis. Medical Hypotheses, 15:385.

Ahlbom BE, Goetz P, Korenberg JR, etal. Molecular analysis of chromosome 21 in a patient with a phenotype of Down syndrome and an apparently normal karyotype. Am J Med Genet 1996; 63:566-572.

Airaksinen EM. Tryptophan treatment of infants with Down syndrome. Annals of Clinical Research 1974; 6:33-38.

Allanson JE, Hughes-Benzie RM, Farkas L. Anthropometric craniofacial pattern profiles in Down syndrome. Proc Greenwood Genet Center 1992; 11:165.(abstract)

Allanson JE, O'Hara P, Farkas LG, Nair RC. Anthropometric craniofacial pattern profiles in Down syndrome. Am J Med Genet 1993; 47:748-752.

Anneren G, Erdman B. Down syndrome -- a gene dosage disease caused by trisomy of genes within a small segment of the long arm of chromosome 21, exemplified by the study of the effects from the superoxidedismutase type 1 (SOD1) gene. APMIS 1993; 40 Supp:71-79.(abstract)

Anneren G, Gustafsson J, Sara VR, Tuvemo T. Normalized growth velocity in children with Down syndrome during growth hormone therapy. J Intell Disabil Res 1993; 37:381-387.(abstract)

Anneren G, Gustavson K-H, Sara VR, Tuvemo T. Growth retardation in Down syndrome in relation to insulin-like growth factors and growth hormone. Am J Med Genet 1991; Supp. 7:59-62.

Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down syndrome: Prevalence, management, and diabetic complications. Diabetic Med 1998; 15:160-163.

Arnold GL, Schultz EG, Richert V, Krogh J, Kearns GL. Effect of amantadine supplementation on dopamine and developmental outcome in Down syndrome. Am J Hum Genet 1995; 57:A82.(abstract)

Auld RM, Pommer AM, Houck IC, Burke F: Vitamin absorption in mongoloid children. A preliminary report. American Journal of Mental Deficiency Research, 63:1010, 1959.

Page xl

Baird PA, Sadovnick AD. Life expectancy to the seventh decade in Down syndrome. Am J Hum Genet 1988; 43:3:A37.(abstract)

Baird PA, Sadovnick AD. Life tables for Down syndrome. Hum Genet 1989; 82:291-292.

Bambrick LL, Yarowsky PJ, Krueger BK. Glutamate as a hippocampal neuron survival factor: an inherited defect in the trisomy 16 mouse. Proc Natl. Acad Sci USA 1995; 92:9692-9696.(abstract)

Barkin RM, Weston WL, Humbert JR, Sunada K: Phagocytic function in Down syndrome. II. Bactericidal activity and phagocytosis. Journal of Mental Deficiency Research, 24: 251, 1980.

Barlow PJ, Sylvester PE, Dickerson JWT: Hair trace elements in Down's syndrome patients. Journal of Mental Deficiency Research, 25:161, 1981.

Barreca A, Rasore QA, Acutis MS, etal. Assessment of growth hormone insulin like growth factor-I axis in Down syndrome. J Endocrinol Invest 1994; 17:431-436.

Beccaria L, Marziani E, Manzoni P, etal. Further evidence of cholinergic impairment of the neuroendocrine control of GH secretion in Down syndrome. Dement Geriatr Cogn Disord 1998; 9:78-81.

Becker LE, Mito T, Takashima S, Onodera K, and Friend WC, Association of phenotypic abnormalities of Down Syndrome with an imbalance of the genes on chromosome 21. APMIS Suppl 40, Vol 101:57-70, 1993

Bedwal RS, Nair N, Sharma MP, Mathur RS. Selenium -- its biological perspectives. Med Hypotheses 1993; 41:150-159.(abstract)

Bell JA, Pearn JH, Firman D. Childhood deaths in Down's syndrome. Survival curves and causes of death from a total population study in Queensland, Australia, 1976 to 1985. J Med Genet 1989; 26:764-768.

Bidder RT, Gray P, Newcombe RG, Evans BK, Hughes M. The effects of multivitamins and minerals on children with Down syndrome. Dev Med Child Neurol 1989; 31:532-537.

Borghi CBE, Rethoré M-O, Lejeune J, Alperovitch A. Absence of familial association between dementia of Alzheimer type and Down syndrome. Am J Med Genet 1989; 33:545-550.

Borsatto B, Smith Mde A, Garcez EM, Peres CA. Age-associated mosaicism polyploidy in Down syndrome. Mech Aging Dev 1998; 100:77-83.

Bosman GJCGM, Visser FE, De Man AJM, Bartholomeus IGP, De Grip WJ. Erythrocyte membrane changes of individuals with Down's syndrome in various stages of Alzheimer-type dementia. Neurobiol Aging 1993; 14:223-228.

Brugge K, Katzman R, Hill LR, Hansen LA, Saitoh T. Serological 1-antichymotrypsin in Down's syndrome and Alzheimer's disease. Ann Neurol 1992; 32:193-197.

Brugge KL, Nichols SL, Salmon DP, etal. Cognitive impairment in adults with Down's syndrome: Similarities to early cognitive changes in Alzheimer's disease. Neurology 1994; 44:232-238.

Brattstrom L, etal: Homocysteine, Factor VII and antithrombin with different gene dosage for CBS. J. Inherit. Metab. Dis., 12:475, 1989

Bugiani O, Giaccone G, Frangione B, Ghetti B, Tagliavini F: Alzheimerís patients: pre-amyloid deposits are more widely distributed than senile plaques throughout the central nervous system. Neurosci. Lett., 103:263-268, 1989

Page xli

Bugiani O., Giaccone G, Verga L, Pollo B, Ghetti B, Frangione B, Tagliavini F: Alzheimer patients and Down patients: abnormal presynaptic terminals related to cerebral amyloid deposits. Neurosci. Lett., 119:56-59, 1990

Burger PC, Vogel FS: the development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Downís syndrome. American Journal of Pathology, 73:457, 1973.

Burgio R, Ugazio A, Nespoli L, Marcioni AF, Bottelli AM, Pasquali F: Derangementís of immunoglobulin levels, phtyohemagglutinin responsiveness and T and B cell markers in Downís syndrome at different ages. European Journal of Immunology, 5:600, 1975.

Burt DB, Loveland KA, Primeaux-Hart S, etal. Dementia in adults with Down syndrome: diagnostic challenges. Am j mental retardation 1998; 103:130-145.

Busciglio J and Yankner BA: Apoptosis and increased generation of reactive oxygen species in Downís Syndrome neurons in vitro. Nature, 378:776-779, 1995

Carmeliet G, David G, Cassimann JJ. Cellular aging of Alzheimer disease and Down syndrome cells in culture. Mutat Res 1991; 256:221-231.(abstract)

Castells S, Torrado C, Bastian W. Growth hormone deficiency in Down's syndrome children. J Intell Disabil Res 1992; 36:29-43.(abstract)

Ceballos-Picot I. Transgenic mice overexpressing copper/zinc superoxide dismutase: a model for the study of radical mechanisms and aging. Seances Soc Biol Fil 1993; 187:308-323.(abstract)

Chadefaux, etal: Cystathionine beta synthase: Gene dosage effect of trisomy 21. Biochem. Biophys. Res. Comm., 128:40, 1988

Chadefaux, etal: Is absence of atheroma in Down syndrome due to decreased homocysteine levels? (letter) Lancet, 1:741, 1988

Chandra RK: Immunocompetence as a functional index of nutritional status. British Medical Bulletin, 37:89, 1981.

Chirocolo, M., etal. (1993) Enhanced DNA repair in lymphocytes of Down syndrome patients: the influence of zinc nutritional supplementation. Mutat. Res. 295: 105-111.

Cichon P, Crawford L, Grimm WD. Early onset peridontitis associated with Down syndrome. Clinical Intervention study. Annals of Peridontology 1998; 3:370-380.

Cole G, Neal JW, Singhrao SK, Jasani B, Newman GR: The distribution of amyloid plaques in the cerebellum and brain stem in Downís Syndrome and Alzheimerís disease: a light microscopical analysis. Acta Neuropathol., 85:542-552, 1993

Cooley WC, Graham Jr JM. Common syndromes and management issues for primary care physicians; Down syndrome--An update and review for the primary Pediatrician. Clin Pediatr 1991; 30:4:233-253.

Cooper S-A, Collacott RA. Mania and Down's syndrome. Br J Psychiatry 1993; 162:739-743.

Cork LC. Neuropathology of Down syndrome and Alzheimer disease. Am J Med Genet 1991; Supp. 7:282-286.

Cosgrave MP, McCarron M, Anderson M, Tyrell J, Gill M, Lawlor BA. Cognitive decline in Down syndrome: A validity/reliability study of the test for severe impairment. Am J Mental Retardation 1998; 103:193-197.

Page xlii

Cossarizza A, Monti D, Montagnani G, etal. Precocious aging of the immune system in Down syndrome: Alteration of B lymphocytes, T-lymphocyte subsets and cells with natural killer markers. Am J Med Genet 1991; Supp. 7:213-218.

Crastes de Paulet A. Free Radicals and Aging. Laboratorie de Biochemi A, Institut de Biologie, Montpellier 1993; (abstract)

Cremers MJG, Ramos L, Bol E, Van Gijn J. Radiological assessment of the atlantoaxial distance in Down's syndrome. Arch Dis Child 1993; 69:347-350.

Crate N, Gosset Ph, Theophile D, etal. Mapping the Down syndrome chromosome region. Eur J Hum Genet 1993; 1:51-63.

Crombie M, Gunn P. Early intervention, families, and adolescents with Down syndrome. International Journal of Disability, Development & Education 1998; 45.

Cruz Pastor M, Sterra C, Dolade’ M, etal. Antioxidant enzymes and fatty acid status in erythrocytes in Down syndrome. Clin Chem 1998; 14:924-929.

Cunningham C, Turner S, Sloper P, Knussen C. Is the appearance of children with Down syndrome associated with their development and social functioning? Dev Med Child Neurol 1991; 33:285-295.

Dalton AJ, Crapper-McLachlan DR. Clinical expression of Alzheimer's disease in Down's syndrome. In: Psychiatric Perspectives in Mental Retardation: Psychiatric Clinics of North America 9:4 December 1986. New York, New York: W.B. Saunders, 1986:659-670.

Davisson MT, Schmidt C, Akeson EC. Segmental trisomy of murine chromosome 16: A new model system for studying Down syndrome. In: Progress in Clinical and Biologic Research V 360

Day T, Taylor PD. Drive and evolution of meiotic nondisjunction and trisomy in humans. Proc natl Acad Sci USA 1998; 95:2361-2365.

Molecular Genetics of Chromosome 21 and Down syndrome. New York: Wiley-Liss, Inc., 1990:263-280.

De Berker DAR, Wilson CL, Millard PR. Reactive perforating collagenosis and Down's syndrome. Br J Dermatol 1992; 126:71-73.

de Haan JB, Cristiano F, Iannello R, Blandier C, Kelner MJ, Kola I. Elevation of the ratio of CU/Znsuperoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. Hum Mol Genet 1996; 5:283-292.

De La Monte SM and Hedley-Whyte T: Small cerebral hemispheres in adults with Downís syndrome: contributions of developmental arrest and lesions of Alzheimerís Disease. J. Neuropathol. Exp. Neurol., 49:509-520, 1990

Delabar J-M, Theophile D, Rahmani Z, etal. Molecular mapping of twenty-four features of Down syndrome on chromosome 21. Eur J Hum Genet 1993; 1:114-124.

Dickinson MJ, Lekh S, Singh I, Langa A. Adaptive behaviour scale in Down's syndrome. Br J Psychiatry 1993; 162:423-424.

Druzhyna N, Nair RG, Ledoux SP. Defective repair of oxidative damage in mitochondrial DNA in Down syndrome. Mutat Res 1998; 409:81-89.

Page xliii

Ebadi M, Iversen PL, Hao R, etal. Expression and regulation of brain metallothionen. Neurochem Int 1995; 27:1-22.(abstract)

Epstein CJ. Down syndrome (trisomy 21). In: Scriver CR, Beaudet AL, Sly WS, Valle DL, eds. The Metabolic Basis of Inherited Disease. 15Th ed. New York: McGraw Hill, 1989:291-326.

Epstein CJ. The consequences of chromosome imbalance. Am J Med Genet 1990; Supp 7:31-37.

Epstein CJ, Korenberg JR, Anneren G, etal. Protocols to establish Genotype-Phenotype correlations in Down syndrome. Am J Hum Genet 1991; 49:207-235.

Epstein CJ, Trsiomy 21 and the nervous system: From cause to cure. In Epstein CJ (ed): The neurobiology of Down Syndrome. Raven Press, New York 1986, pp1-15

Evans DA, Funkenstein HH, Albert MS, etal: Prevalence of Alzheimerís disease in a community of older person. Higher than previously reported. JAMA, 262:2551-2556, 1989

Evenhuis HM. The natural history of dementia in Down's syndrome. Arch Neurol 1990; 47:263-267.

Farrar G, Altmann P, Welch S, etal. Defective gallium-transferrin binding in Alzheimer disease and Down syndrome: Possible mechanism for accumulation of aluminum in brain. Lancet 1990; 335:747-750.

Ferrier LJ, Bashir AS, Meryash DL, Johnston J, Wolff P. Conversational skills of individuals with fragile-X syndrome: A comparison with autism and Down syndrome. Dev Med Child Neurol 1991; 33:776-788.

Fishler K, Koch R. Mental development in Down syndrome mosaicism. Am j mental retardation 1991; 96:345-351.

Flickinger KS and Culp LA: Dermal fibroblasts from Downís syndrome. Exp. Cell Research, 189:189-201, 1990

Franchesi C, Licastro F, Paolucci P, Masi M, Cavicchi S, Sannotti M: T and B lymphocyte subpopulations in Down's syndrome. A study on non-institutionalized subjects. Journal of Mental Deficiency Research, 22:179, 1978.

Franceschi C, Monti D, Cossarizza A, Fagnoni F, Passeri G, Sansoni P. Aging, longevity, and cancer: Studies in Down's syndrome and centenarians. Ann NY Acad Sci 1991; 621:428-440.

Friedman DL, Kastner T, Pond WS, O'Brien DR. Thyroid dysfunction in individuals with Down syndrome. Arch Intern Med 1989; 149:1990-1993.

Gahtan E, Auerbach JM, Groner Y, Segal M. Reversible impairment of long-term potentiation in transgenic Cu/Zn-SOD mice. European Journal of Neuroscience 1998; 10:538-544.

Gakhal B, Scott CS, Macnab AJ. Comparison of morphine requirements for sedation in Down syndrome and non-Down patients following paediatric cardiac surgery. Paediatric Anaesthesia 1998; 8:229-233.

Galdzicki Z, Coan EJ, Rapoport SI, Stoll J. Increased expression of voltage-activated calcium channels in cultured hippocampal neurons from trisomy 16 mouse, a model for Down syndrome.

Geggei RL, O'Brien JE, Feingold MF. Development of valve dysfunction in adolescents and young adults with Down syndrome and no known congenital heart disease. Journal of Pediatrics 1993; 122:5:1:821-823.

George EK, Mearin L, Bouquet J, etal. High frequency of celiac disease in Down syndrome. Journal of Pediatrics 1996; 128:4:555-557.

Page xliv

Gericke CS, Hesseling PB, Brink S, Tiedt FC: Leukocyte Utrastructure and folate metabolism in Downís syndrome. South African Medical Journal, 51: 369, 1977.

Gershwin ME, Crinella FM, Castles JJ, Trent JKT: Immunologic characteristics of Downís syndrome. Journal of Mental Deficiency Research, 21:237, 1977.

Goiffin B: Coprologie fonctionnelle. Encyclopedic Medic-chirugicale. Estoma-Intestin 90-10: A10 and A-20: 4, 1977

Golden JA and Hyman, BT: Development of the superior temporal neocortex is anomalous in trisomy 21. J Neuropath. Exp. Neuro., 53(5):513-520, 1994

Golden GS. Controversies in the therapies for children with Down syndrome.
PIR 1984; 6:4:116-120.

Gradwohl RBH: Clinical laboratory methods and diagnosis. 5th edition, Vol. 2, PP 1261-1314. The CV Mosby Company St. Louis, 1956

Greber-Platzer S, Schatzmann-Turhani D, Wollenek G, Lubec G. The current hypothesis of gene dosage effects of trisomy 21: Ets-2 encoded on chromosome 21 is not overexpresseed in the hearts of patients with Down syndrome. Biochemical & Biophysical Research communications 1999; 254:395-399.

Greenberger NJ, Toskes PP: Approche díun patient porteur díune maladie pancratique. P.1607 in Harrison's Principels de medicine interne. Med franaise, Vol. 2 (Isselbacher etal, eds.) Flammarion, Paris, 1982

Gregor P, Gaston SM, Yang X, etal. Genetic and physical mapping of the GLUR5 glutamate receptor gene on chromosome 21. Hum Genet 1994; 94:565-570.(abstract)

Hardy J, Crook R, Perry R, Raghavan R, Roberts G. ApoE genotype and Down's syndrome. Lancet 1994; 343:979-980.

Hassin-Baer S, Wertman E, Raphael M, Stark V, Chapman J, Michaels on DM. Antibodies from Down's syndrome patients bind to the same cholinergic neurofilament protein recognized by Alzheimer's disease antibodies. Neurology 1992; 42:551-555.

Heblein S and Klein LV: National Association Down Syndrome News, 11:1-3, 1994

Hemdal P, Corwin J, Oster H. Olfactory identification deficits in Down's syndrome and idiopathic mental retardation. Neuropsychologia 1993; 31:977-984.

Hestnes A, Borud O, Lunde H, Gjessing L. Cystathionuria in Down syndrome. J Ment Def Res 1989; 33:261-265.(abstract)

Hestnes A, Stovner LJ, Husoy O, Folling I, Fougner KJ, Sjaastad O. Hormonal and biochemical disturbances in Down's syndrome. J Ment Def Res 1991; 35:179 193.(abstract)

Hestnes A, Stovner LJ, Husoy O, Folling I, Sjaastad O. Somatomedin C (insulin-like growth factor I) in adults with Down syndrome. J Ment Def Res 1991; 35:204-208.(abstract)

Hilhorst MI, Brink M, Wauters EAK, Houwen RHJ. Down syndrome and celiac disease: Five new cases with a review of the literature. Eur J Pediatr 1993; 152:884-887.

Holland AJ, Hon J, Huppert FA, Stevens F, Watson P. Population-based study of the prevalence and presentation of dementia in adults with Down syndrome. Br J Psychiatry 1998; 172:493-498.

Page xlv

Howell SJL, Foster KJ, Rechless J: Protracted survival in patients with Downís syndrome. British Medical Journal, 287:1429m 1983

Hsiang YH, Berkovitz GD, Bland GL, Migeon CJ, Warren AC. Gonadal function in patients with Down Syndrome. Am J Med Genet 1987; 27:449-458.(abstract)

Hultcrantz E, Svanholm H. Down syndrome and sleep apnea--A therapeutic challenge. Int J Pediatr Otorhinolaryngol 1991; 21:263-268.

Huret JL, Delabar JM, Marlhens F, Aurias A, Nicole A, Berthier M, Tanzer J, Sinet PM: Down syndrome with duplication of a region of chromosome 21 containing the CuZn superoxide dismutase gene without detectable karyotypic abnormality. Hum. Genet., 75:251-257, 1987

Jenkins EC, Schupf N, Genovese M, etal. Increased low-level chromosome 21 mosaicism in older individuals with Down syndrome. Am J Med Genet 1997; 68:147-151.

Jernigan TL, Bellugi U, Sowell E, Doherty S, Hesselink JR. Cerebral morphologic distinctions between Williams and Down syndromes. Arch Neurol 1993; 50:186-191.

Joblin A. Motor development in School-aged children with Down syndrome. International Journal of Disability, Development & Educatoin 19998; 45.

Klewer SE, Krob SL, Kolker SJ, Kitten GT. Expression of type VI collagen in the development of the mouse heart. Dev Dyn 1998; 211:248-255.

Kohen D, Wise PH. Autoantibodies in Down's syndrome. Lancet 1992; 340:430.

Kola I, Hertzog PJ. Down syndrome and mouse models. Curr Opin Genet Dev 1998; 8:316-321.

Korenberg JR etal: Down syndrome phenotypes. The consequence of chromosomal imbalance. Proc. Natl. Acad. Sci. USA, 91:4997-5001, May, 1994

Korenberg JR. Toward a molecular understanding of Down syndrome. Prog Clin Biol Res 1993; 384:87-115.

Korenberg JR, Bradley C, Disteche CM. Down syndrome: Molecular mapping of the congenital heart disease and duodenal stenosis. Am J Hum Genet 1992; 50:294-302.

Korenberg JR, Kawashima H, M.-Pulst S, Allen L, Magenis RE, Epstein CJ. Down syndrome: Toward a molecular definition of the phenotype. Am J Med Genet 1991; Supp. 7:91-97.

Korenberg JR, Kawashima H, Pulst SM, etal. Molecular definition of a region of chromosome 21 that causes features of the Down syndrome phenotype. Am J Hum Genet 1990; 47:236-246.

Labudova O, Fang-Kirchner S, Cairns N, Moenkmann H, Yeghiazaryan K, Lubec G. Brain vasopressin levels in Down syndrome and Alzheimer disease. Brain Res 1998; 806:55-59.

Lai F, Williams RS. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol 1989; 46:849-853.

LaPerchia P. Behavioral disorders, learning disabilities and megavitamin therapy. Adolescence 1987; XXII 87:729-738

Lejeune J, Pathogenesis of Mental Deficiency in Trisomy 21. Am.J.Med.Genet. 7:20-30, 1990

Page xlvi

Lejeune J, etal: Homocysteine and the methotrexate toxicity in trisomy 21. Cancer Chemother. Pharmacol., 27:331, 1991

Lejeune J, Peeters M, Rethoré; M-O, De Blois MC. Down syndrome and 3,3',5'-triiodothyronine. Am J Dis Child 1990; 144:1:19.

Lejeune J, Peeters M, Rethoré MO, De Blois MC. Homocsyteine and the methotrexate toxicity in trisomy 21. Cancer Chemotherapy Pharmacology 1991; 27:331-332.(abstract)

Lejeune J, Rethoré MO, De Blois MC, Peeters M. Psycose infantile, syndrome pseudo-Alzheimer, et trisomie 21: Essai de medication par l'acide folinique: rapport preliminaire. Therapie 1989; 44:115-121.

Lejeune J, Rethoré MO, De Blois MC, etal. Amino acids and trisomy. Ann Genet 1992; 35:8-13.

Levine OR. Down's syndrome, fetal alcohol syndrome, and upper airway obstruction. Am J Dis Child 1987; 14:478.

Levitt GA, Stiller CA, Chessells JM. Prognosis of Down's syndrome with acute leukaemia. Arch Dis Child 1990; 65:212-216.

Levo Y, Green P: Downís syndrome and autoimmunity. The American Journal of Medical Sciences, 273:95, 1977

Lockitch G, Puterman M, Godolphin W, Sheps S, Tingle AJ, Quigley G. Infection and immunity in Down syndrome: A trial of long-term low oral doses of zinc. Journal of Pediatrics 1989; 114:5:781-787.

Magnusson CG, Nordvall SL, Anneren G. Differential effect of selenium supplementation in immunoglobulin levels in Down syndrome. Acta Paediatr 1998; 86: 1385-1386.

Mann DMA, Royston MC, Ravindra CR. Some morphometric observations on the brains of patients with Down's syndrome: Their relationship to age and dementia. J Neurol Sci 1990; 99:153-164.

Marcus CL, Keens TG, Bautista DB, von Pechmann WS, Ward SLD. Obstructive sleep apnea in children with Down syndrome. Pediatrics 1991; 88:1:132-139.

Marino B, Corno A, Guccione P, Marcelletti C. Ventricular septal defect and Down's syndrome. Lancet 1991; 337:245-246.

Marino B, Papa M, Guccione P, Corno A, Marasini M, Calabro; R. Ventricular septal defect in Down syndrome. Am J Dis Child 1990; 144:544-545.

Marino B, Vairo U, Corno A, etal. Atrioventricular canal in Down syndrome. Am J Dis Child 1990;144:10:1120-1122.

Maroudias N, Economides J, Christodoulou P, Helidonis E. A study on the otoscopical and audiological findings in patients with Down's syndrome in Greece. Int J Pediatr Otorhinolaryngol 1994; 29:43-49.

Martich V, Ben-Ami T, Yousefzadeh DK, Roizen NJ. Hypoplastic posterior arch of C-1 in children with Down syndrome:Y´ A double jeopardy. Radiology 1992; 183:125-128.

Mastroiacovo P, Bertollini R, Corchia C. Survival trends in Down syndrome. Lancet 1990; 335:1278-1279.

Page xlvii

Matin MA, Sylvester PE, Edwards D, Dickerson JWT: Vitamin and zinc status in Downís syndrome. Journal of Mental Deficiency Research, 25:121, 1981.

McCoy EE, Sneddon JM: Decreased calcium content and CAa2+ uptake in Downís syndrome blood platelets. Pediatric Research, 18:914, 1984.

Mattson MP, Barger SW, Cheng B, Lieberburg I. beta-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer disease. Trends Neurosci 1993; 16:409-414.(abstract)

McCormick MK, Schinzel A, Petersen MB, etal. Molecular genetic approach to the characterization of the "Down syndrome region" of chromosome 21. Genomics 1989; 5:325-331.

McQuillan CI, Choo KH. Comparison of total cellular DNA, mRNA, and rRNA levels between normals and Down syndrome patients. J Inherited Metab Dis 1992; 15:112-120.

Mirochhnitchenko O and Inouye M: Effect of overexpression of human Cu, Zn superoxide dismutase in transgenic mice on macrophage functions. Department of Biochemistry. J. Immunol., 156(4):1578-86, Feb, 1996

Moore J, Englert E, Bigler AM, Clark RW: Simple fecal tests of absorption. A prospective study and critique. American Journal of Digestive Diseases,Y´ 16:97, 1971.

Muenke M, Bone LJ, Mitchell HF, etal. Physical mapping of the holoprosencephaly critical region in 21q22.3, exclusion of SIM2 as a candidate gene for holoprosencephaly,
and mapping Sim2 to a region of chromosome 21 important for Down syndrome. Am J Hum Genet 1995; 57:1074-1079.

Murdoch JC, Gray CA, McLarty DG, Ratcliffe JG. Pituitary function in Down syndrome. J Ment Def Res 1978; 22:273-275.(abstract)

Napolitano G, Palka G, Grimaldi S, etal. Growth delay in Down syndrome and zinc sulphate supplementation. Am J Med Genet 1990; 7 Supplement:63-65.(abstract)

Nicolaides P, Petersen MB. Origin and mechanisms of non-disjunction in human autosomal trisomies. Human Reproduction 1998; 13:313-319.

Norstrom M, Kjellstrom T. Age dependency of cystathionine beta-synthetase activity in human fibroblasts in homocystinemia and atherosclerotic vascular disease. Atherosclerosis 1992; 94:213-221.(abstract)

Nowak TV, Gjishan FK, Schulze-Delrieu K: Celiac sprue in Downís syndrome: considerations on a pathogenic link. American Journal of Gastroenterology, 78:385, 1983

Novo E, Garcia MI, Laverge J. Nonspecific immunity in Down syndrome: A study of chemotaxis, phagocytosis, oxidative metabolism, and cell surface marker expression of polymorphonuclear cells. Am J Med Genet 1993; 46:384-391.

Negrave J, Vertongen F, Cauchie P, Gnat D, Molle L. Selenium and glutathione peroxidase in plasma and erythrocytes of Down's syndrome (trisomy 21) patients. J Ment Defic Res 1984; 28:261-268.

O'Brien JM, Geggel R, Feingold MF. Mitral valve prolapse in Down syndrome. Proc Greenwood Genet Center 1990; 9:96-97.

Odetti P, Angelini G, Dapino D, etal. Early glyoxidation damage in brains from Down syndrome. Biochem Biophys Res Commun 1998; 243:849-851.

Page xlviii

O'Dwyer J, Holmes J, Collacott RA. Two cases of obsessive-compulsive disorder in individuals with Down's syndrome. J Nerv Ment Dis 1992; 180:603-604.

Olson JC, Bender JC, Levinson JE, Oestreich A, Lovell DJ. Arthropathy of Down syndrome. Pediatrics 1990; 86:6:931-936.

OMIM (1997). Online Mendelian Inheritance in Man.Victor A. McKusick, etal.URL: http://www3.ncbi.nlm.nih.gov/omim/.

Opitz JM, Gilbert-Barness EF. Reflections on the pathogenesis of Down syndrome. Am J Med Genet 1991; Supp. 7:38-51.

Orlicek SL, Walker MS, Kuhls TL. Severe mycoplasma pneumonia in young children with Down syndrome. Clin Pediatr (Phila ) 1992; 31:409-412.

Page LB and Culver PJ: A syllabus of laboratory examinations in clinical diagnosis. Revised Ed PP 374-380 Harvard University Press, Cambridge MA, 1961.

Palmer CGS, Cronk C, Pustule SM, etal. Head circumference of children with Down syndrome (0-36 months). Am J Med Genet 1992; 42:61-67.

Palmer S. Influence of Vitamin A nurtiture on the immune response: Findings in Children with Down's syndrome. Internat J Vit Nutr Res 1978; 48:188-216.

Pary RJ, Strauss D, White JF. A population survey of bipolar disorder in persons with and without Down syndrome. Down Syndrome Quarterly 1996; 1:1-4.

Pastor MC, Sierra C, Dolade M, etal. Antioxidant enzymes and fatty acid status in erythrocytes of Down syndrome patients. Clin Chem 1998; 44:924-929.

Pearlson GD, Warren AC. Aging and brain weight in Down's syndrome. Neurology 1989; 39:1407. Peeters MA, etal: In vivo folic acid supplementation partially corrects methotrexate toxicity in patients with Down syndrome. Brit. J. Haematol., 89:678, 1995

Peeters MA, Megarbane A, Cattaneo F, Rethoré; MO, Lejeune J. Differences in purine metabolism in patients with Down syndrome. J Intell Disabil Res 1993; 37:491-505.(abstract)

Peled-Kamar M, Lotem J, Okon E, Sachs L, Groner Y: Thymic abnormalities and enhance apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing CU/Zn-superoxide dismutase: Implications for Down syndrome. Department of Molecular Genetics and Virology, Weizman Institute of Science, Rehovot, Israel. EMBO J, Oct 16:14(20):4985-4931 1995.

Pierotti AR, Harmar AJ, Simpson J, Yates CM. High-molecular weight forms of somatostatin are reduced in Alzheimer disease and Down syndrome. Neurosci Lett 1986; 63:141-146.(abstract)

Popovitch ER, Wisniewski HM, Barcikowska M, Silverman W, Bancher C, Sersen E, Wen GY: Alzheimer neuropathology in non-Downís syndrome mentally retarded adults. Acta. Neuropathol., 80:362-367, 1990

Prasad M, Moodie D, Sterba R, Murphy D, Rosenkranz E, Homa A. Long term follow-up of children with Down syndrome with cardiac lesions. Clin Pediatr 1990; October:569-574.

Prasher VP, Krishnan VHR. Mental disorders and adaptive behaviour in people with Down's syndrome. Br J Psychiatry 1993; 162:848-849.

Page xlix

Prasher VP, Farrer MJ, Kessling AM, West RJ, Barber PC, Butler AC. Molecular mapping of Alzheimer type dementia in Down syndrome. Ann Neurol 1998; 43:380-383.

Prasher VP, Gosling P, Blair J. Role of iron in Alzheimer type dementia in Down syndrome. International Journal of Geriatric Psychiatry 1998; 13.

Prince J, Jia S, Bave U, Anneren G, Oreland L. Mitochondrial enzyme deficiencies in Down syndrome. J Neural Trans Park Dement Sect 1994; 8:171-181.(abstract)

Pruess JB, Fewell RR, Bennett FC. Vitamin therapy and children with Down syndrome: A review of research. Exceptional Children 1989; 55:336-341.

Pueschel SM. Growth, thyroid function, and sexual maturation in Down syndrome. Growth, Genetics, & Hormones 1990; 6:1:1-5.

Pueschel SM. Clinical aspects of Down syndrome from infancy to adulthood. Am J Med Genet 1991; Supp. 7:52-56.

Pueschel SM, Louis S, McKnight P. Seizure disorders in Down syndrome. Arch Neurol 1991; 48:318-320.

Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-Hydroxytryptophan and pyridoxine: Their effects in young children with Down's syndrome. Am J Dis Child 1980; 134:838-844.

Pueschel SM, Scola FH, Pezzullo JC. A longitudinal study of atlanto-dens relationships in asymptomatic individuals with Down syndrome. Pediatrics 1992; 89:6:1194-1198.

Querfurth HW, Wijsman EM, St George-Hyslop PH, Selkoe DJ. Beta APP mRNA transcription is increased in cultured fibroblasts from the familial Alzheimer disease -1 family. Brain Res Mol Brain Res 1995; 28:319-337.(abstract)

Ragusa L, Valetto MR, Proto C, etal. IGF-I levels in prepubertal children with Down syndrome. Minerva Endocrinologica 1998; 2:31-36.

Rahmani Z, Blouin J-L, Creau-Goldberg N, etal. Down syndrome critical region around D21S55 on proximal 21q22.3. Am J Med Genet 1991; Supp. 7:98-103.

Raji NS, Rao KS. Trisomy 21 and accelerated aging: DNA repair parameters in peripheral lymphocytes of Down syndrome patients. Mech Aging Dev 1998; 100:85-101.

Ravindranath Y, Abella E, Krischer JP, etal. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML Study 8498. Blood 1992; 80:2210-2214.

Reddy VN, Aughton DJ, DeWitte DB, Harper CE. Down syndrome and omphalocele: An underrecognized association. Pediatrics 1994; 93:514-515.

Regland B, Gottfries CG. Slowed synthesis of DNA and methionine is a pathogenetic mechanism common to dementia in Down syndrome, AIDS, and Alzheimer disease? Med Hypotheses 1992; 38:11-19.(abstract)

Reilly J, Klima ES, Bellugi U. Once more with feeling: Affect and language in atypical populations. In: Development and Psychopathology, 2. 2nd ed. Boston: Cambridge University Press, 1990:367-391.

Ridgway D, Benda GI, Magenis RE, etal. Transient myeloproliferative disorder of the Down type in the normal newborn. Am J Dis Child 1990; 144:10:1117-1119.

Page l

Reading CM, McLEay A, Nobile S: Down's syndrome and thiamine deficiency. Journal of Orthomolecular Psychiatry, 8: 4, 1979

Roberts GW, Gentleman DM, Lynch A, Graham DI: Beta A4 amyloid protein deposition in brain after head trauma. Lancet, 338:1422-1423, 1991

Robinson LL, Neglia JP. Epidemiology of Down syndrome and childhood acute leukemia. In: Oncology and Immunology of Down Syndrome. New York: Alan R. Liss, 1987:19-32.

Robson WLM, Leung AKC. Down's syndrome and renal abnormalities. Pediatr Nephrol 1993; 7:775.

Roizen NJ, Mets MB, Blondis TA. Ophthalmic disorders in children with Down syndrome. Dev Med Child Neurol 1994; 36:594-600.

Rothman MM, Katz AB: Analysis of feces in Gastroenterology. 2nd edition vol. 2 p694 HL Bockus ed. WB Saunders Company. Philadelphia, 1964

Rowe IF, Ridler MAC, Gibberd FB. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet 1989; 2:229.

Roy A, Roy M, Butler AC. Atlantoaxial instability in monozygotic twins with Down's syndrome. J R Soc Med 1993; 86:296.

Rubin SS, Rimmer JH, Chicoine B, Braddock D, McGuire DE. Overweight prevalence in persons with Down syndrome. Mental Retardation 1998; 36:175-181.

Russell BG, Kjaelig; i. Tooth agenesis in Down syndrome. Am J Hum Genet 1995; 55:466-471. Sacchi N, Nalbantoglu J, Sergovich FR, Papas TS. Human ETS2 gene on chromosome 21 is not rearranged in Alzheimer disease. Proc Natl Acad Sci USA 1988; 85:7675-7679.

Sago H, Carlesen EJ, Smith DJ, etal. Ts1Cje a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities. Proc natl Acad Sci USA 1998; 95:6256-6261.

Sansone R, Pierluigi M, Carobbi S, Cominetti M, Strigini P. Disomic homozygosity and leukemia in Down's syndrome. Hum Genet 1990; 85:386.

Savage AR, Petersen MB, Pettay D, etal. Elucidating the mechanisms of paternal non-disjunction of chromosome 21 in humans. Hum Mol Genet 1998; 7:1221-1227.

Schapiro MB, Luxenberg JS, Kaye JA, Haxby JV, Friedland RP, Rapoport SI. Serial quantitative CT analysis of brain morphometrics in adult Down's syndrome at different ages. Neurology 1989; 39:1349-1353.

Schapiro MB, Rapoport SI. Aging and brain weight in Down's syndrome. Reply. Neurology 1989; 39:1407-1408.

Schmid F Von, Christeller S, Rehm W: Untersuchungen zum Status von Vitamin B1, B2 und B6 bein Down Syndrom. Fortschritte Der Medizin, 93:1-170, 1975

Schupf N, Kapell D, Nightingale B, Rodriguez A, Tycko B, Mayeaux R. Earlier onset of Alzheimer disease in men with Down syndrome. Neurology 1998; 50:991-995.

Schwaiger H, Weirich HG, Brunner P, etal. Radiation sensitivity of Down's syndrome fibroblasts might be due to overexpressed Cu/Zn-superoxide dismutase (EC 1.15.1.1). Eur J Cell Biol 1989; 48:79-87.

Page li

Schwartz PJ, Berger UV, Coyle JT. Mice transgenic for copper/zinc superoxide dismutase exhibit increased markers of biogeneic amine function. J Neurochem 1995; 65:660-669.(abstract)

Schwartz PJ, Coyle JT. Effects of the overexpression of the cytoplasmic copper-zinc superoxide dismutase on the survival of neurons in vitro. Synapse 1998; 29:206-212.

Schweber MS. Alzheimer's disease and Down syndrome. Prog Clin Biol Res 1989; 317:247-267.

Shapiro BL. The environmental basis of the Down syndrome phenotype. Dev Med Child Neurol 1994; 36:84-90.

Sharav T, Collins RM, Baab PJ. Growth studies in infants and children with Down's syndrome and elevated levels of thyrotropin. Am J Dis Child 1988; 142:1302-1306.

Silverman W, Popovitch ER, Schupf N, Zigman WB, Rabe A, Sersen E, Wisniewski HM: Alzheimer neuropathology in mentally retarded adults: statistical independence of regional amyloid plaque and neurofibrillary tangle densities. Acta Neuropathol., 85:260-266, 1993

Sinet P-M, Theophile D, Rahmani Z, etal. Molecular mapping of the Down syndrome phenotype on chromosome 21. Prog Clin Biol Res 1993; 384:63-86.

Smith GF, Spiker D, Peterson CP, Cicchetti D, Justine P. Use of megadoses of vitamins with minerals in Down syndrome. Journal of Pediatrics 1984; 105:228-234.

Smith MA, Borsatto B. Down syndrome aging, and fragile sites. Mech Aging Dev 1998; 101:167-173.

Smith ML, Golitz LE, Morelli JG, Weston WL, Markewich G. Milialike idiopathic calcinosis cutis in Down's syndrome. Arch Dermatol 1989; 125:1586-1587.

Snow AD, Mar IL, Nochlin D. Gkiguchi RT, Kimata K, Koiko Y, Wight TN: Early accumulation of heparin sulphate in neurons and in the beta-amyloid protein containing lesions of Alzheimerís Disease and Down syndrome. Am. J. Pathol., 137:1253-1267, 1990

Sobel AE, Straluzza M, Sherman BS, Elkan B, Morgenstern SW, Marius N, Meisel A: Vitamin absorption and other blood composition studies in mongolism. American Journal of Mental Deficiency Research, 62:642, 1958

Solitare GB. Aging and brain weight in Down's syndrome. Neurology 1990; 40:729.

Spencer K, Carpenter P. Estimating risk of Down's syndrome. Br Med J 1991; 302:1536-1537.

Stafstrom CE, Konkol RJ. Infantile spasms in children with Down syndrome. Dev Med Child Neurol 1994; 36:576-585.

Stafstrom CE, Patxot OF, Gilmore HE, Wisniewski KE. Seizures in children with Down syndrome: Etiology, characteristics and outcome. Dev Med Child Neurol 1991; 33:191-200.

Stebbens VA, Dennis J, Samuels MP, Croft CB, Southall DP. Sleep related upper airway obstruction in a cohort with Down's syndrome. Arch Dis Child 1991; 66:1333-1338.

Strigini P, Sansone R, Carobbi S, Pierluigi M. Radiation and Down's syndrome. Nature 1990; 347:717.

Sullivan TJ, Clarke MP, Brazel S, Morin JD, Pashby RC. Congenital lacrimal fistula associated with Down's syndrome. Am J Ophthalmol 1992; 113:215-216.

Page lii

Sutnick AL, London WT, Blumberg BS, Gertsley BJ: Susceptibility to leukemia: immunologic factors in Downís syndrome. Journal of the National Cancer Institute, 47:923, 1971.

Symon DNK, Stewart L, Russel T: Abnormally high sweat osmolality in children with Downís syndrome. Journal of Mental Deficiency Research, 29:202,
1985

Symon DNK, Stewart L, Russel T: Abnormally high sweat osmolality in children with Down’s syndrome. Journal of Mental Deficiency Research, 29:202,1985.

Takanashi J, Sugita K, Honda A, Niimi H. Moyamoya syndrome in a patient with Down syndrome presenting with chorea. Pediatr Neurol 1993; 9:396-398.

Thase ME: Longevity and mortality in Downís syndrome. Journal of Mental Deficiency Research, 26: 117, 1982.

Torres C, Buceta J. Effect of parental intervention on motor development in Down syndrome infants between the birth and age two years. British Journal of Developmental Disabilities 1998; 44:87.

Tyrrell J, Cosgrave M, Hawi Z, etal. A protective effect of apolipoprotein E e2 allele on dementia in Down syndrome. Biologic Psychiatry 1998; 43:397-400.

Ugazio AG, Maccario R, Notarangelo LD, Burgio GR. Immunology of Down syndrome: A review. Am J Med Genet 1991; Supp. 7:204-212.

Van Camp G, Stinissen P, Van Hul W, etal. Selection of human chromosome 21-specific DNA probes for genetic analysis in Alzheimer's dementia and Down syndrome. Hum Genet 1989; 83:58-60.

Van Dyke DC, Lang DJ, van Duyne S, Heide F, Chang H. Cell therapy in children with Down syndrome: A retrospective study. Pediatrics 1990; 85:79-84.

Van Dyke DC, Harper DC, Dyken ME. Alzheimer’s disease and Down syndrome. Down syndrome Quarterly 1998; 3:1-11.

Verga L, Frangione B, Tagliavini F, Giaccone G, Migheli A, Bugiani O. Alzheimer patients and Down patients: Cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci Lett 1989; 105:294-299.

Wang PP, Bellugi U. Williams syndrome, Down syndrome, and cognitive neuroscience. Am J Dis Child 1993; 147:1246-1251.

Weathers C. Effects of nutritional supplementation on IQ and certain other variables associated with Down syndrome. Am J Ment Defic 1983; 88:214-217.

Webb N, Hebert D, Arbus G. Renal replacement therapy in Down's syndrome. Pediatr Nephrol 1993; 7:771.

Wilcox WD. Abnormal serum uric acid level in children. Journal of Pediatrics 1996; 128: June:731-741.

Williams CA, Quinn H, Wright EC, Sylvester PE, Gosling PJH, Dickerson JWT: Xylose absorption in Down’s syndrome. Journal of Mental Deficiency Research, 29:173, 1985.

Wisniewski KE and Schmidt-Sidor K, Postnatal delay of myelin formation in brains from Down Syndrome infants and children. Clin Neuropathol 8:55-62, 1989

Wisniewski HM, Wegiel J, Popovitch ER: Age-associated development of diffuse and thioflavin-s-positive plaques in Down syndrome. Devel. Brain Dysfunction, in press

Page liii

Wisniewski KE. Down syndrome children often have brain with maturation delay, retardation of growth , and cortical dysgenesis. Am J Med Genet 1991; Supp. 7:274-281.

Wolraich ML, Siperstein GN, Reed D. Doctors' decisions and prognostications for infants with Down syndrome. Dev Med Child Neurol 1991; 33:336-342.

Zipursky A, Doyle J. Leukemia in newborn infants with Down syndrome. Leuk Res 1993; 17:195.
Zori RT, Schatz DA, Ostrer H, Williams CA, Spillar R, Riley WJ. Relationship of autoimmunity to thyroid dysfunction in children and adults with Down syndrome. Am J Med Genet 1991; Supp. 7:238-241.

Zori RT, Schatz DA, Ostrer H, Williams CA, Spillar R, Riley WJ. Relationship of autoimmunity to thyroid dysfunction in children and adults with Down syndrome. Am J Med Genet 1991; Supp. 7:238-241.

4) References; Stacking the Deck in Your Child’s Favor; Swenson

Page liv

Dasaeva LA. Influence of piracetam on occupationally important functions of hypertensive patients facing psychoemotional strain at work. Meditsina Truda i Promyshlennaya Ekologiya 10: 26-28, 1995.

Dasaeva LA and Vermel AE. Antihypertensive and nootropic drugs in the treatment of hypertensive subjects exposed to occupational stress. Terapevticheskii Arkhiv 68(12): 60-3, 1996.

Deberdt W. Interaction between psychological and pharmacological treatment in cognitive impairment.Life, Sciences 55(25-26): 2057-66, 1994.

Dukes MNG (Editor), Meyler's Side Effects of Drugs (13th Edition), Elsevier Science, Amsterdam, 1996.

Enderby P, Broeckx J, Hospers W, Schildermans F and Deberdt W. Effect of piracetam on recovery and rehabilitation after stroke: A double-blind, placebo-controlled study. Clinical Neuropharmacology 17(4): 320-31, 1994.

Genkova-Papazova MG and Lazarova-Bakarova MB. Piracetam and fipexide prevent PTZ-kindlingprovoked amnesia in rats. European Neuropsychopharmacology 6(4): 285-90, November 1996.

Germonpre P, Reper P and Vanderkelen A. Hyperbaric oxygen therapy and piracetam decrease the early extension of deep partial-thickness burns. Burns 22(6): 468-73, September 1996.

Huber W, Willmes K, Poeck K, Van Vleymen B and Deberdt W. Piracetam as an adjuvant to language therapy for aphasia: A randomized double-blind placebo-controlled pilot study. Archives of Physical Medicine and Rehabilitation 78(3): 245-50, 1997.

Ikeda A, Shibasaki H, Tashiro K, Mizuno Y and Kimura J. Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. The Myoclonus/Piracetam Study Group. Movement Disorders 11 (6): 691-700, November 1996.

Karacostas D, Giannopoulos S, Artemis N and Milonas 1. Effect of piracetam on myoclonus secondary to electrocution: A case report. Acta Therapcutica 19(4): 401-4, 1993.

Krapivin SV and Sopyev ZhA. [The effect of preparations with nootropic action when used long-term on the brain bioelectrical activity in rats]. Eksperimentalnaia i Klinicheskaia Farmakologiia 56(1): 6-9, Jan-Feb 1993. "...prolonged injection of piracetam (2 months)...increased and stabilized the predominant peak of EEC spectra power by the Fourier method. Discontinuation (24 hours) of piracetam failed to impair EEG spectra and bioelectrical activity."

Moriau M, Lavenne-Pardonge E, Crasborn L etal. The treatment of severe or recurrent deep venous thrombosis: Beneficial effect of the co-administration of antiplatelet agents with or without rheological effects, and anticoagulants. Thrombosis Research 78(6): 469-82, 1995.

Moriau M etal. Platelet-anti-aggregant and rheological properties of piracetam: A pharmacodynamic study in normal subjects. Arzneimittel-Forschung 43(2): 110-18, 1993.

Mueller WE, Koch S, Scheuer K, Rostock A and Bartsch R. Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochemical Pharmacology 53(2): 135-40, 1997.

Nagornev SN etal. [Pharmacological correction of lipid peroxidation during hypoxia and possibility to enhance human resistance to high altitude by using preparations of the metabolic type of action]. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 7(7): 53-60, 1996.

Nyagolov Y, Dyankov E and Ganchev T. Effects of piracetam on erythropoiesis and leukopoiesis in rats. Acta Physiologica et Pharmacologica Bulgarica 19 (4): 97-100, 1993.

Pan HYM and Ng RP. The effect of Nootropil in a patient on warfarin. European Journal of Clinical

Page lv

Pharmacology 24: 711, 1983. Pimenov LT, Kalinina SA and Churshin AD. Clinical and hemodynamic efficiency of piracetam (Nootropil) in elderly and senile patients with coronary heart disease in the out-patient rehabilitative period. Kardiologiya 32(5):35-7, 1992.

Pimenov LT, Churshin AD and Ezhov AV. Clinical efficacy and hormonal and metabolic reactions in elderly patients with angina treated by piracetam. Kardiologiya 35(11): 30-34, 1995.

Pimenov LT, Churshin AD and Ezhov AD. [Piracetam and tocopherol acetate ability to potentiate clinical effect of antianginal drugs in presenile and senile patients with ischemic heart disease (unstable angina)]. Klinicheskaia Meditsina 75(l): 32-5, 1997.

Promyslov MS and Demchuk ML. Interrelationship between the functional state of the central nervous system and lipid peroxidation level in brain following craniocerebral trauma. Molecular and Chemical Neuropathology 25(l): 69-80, May 1995.

Reynolds JEF (Editor), Martindale: The Extra Pharmacopoeia (31st Edition), Royal Pharmaceutical Society of Great Britain, London, 1996.

Savula MM, Kravchenko NS and Poznanskii AI. (Chemotherapy of destructive pulmonary tuberculosis with antioxidants and antihypoxic agents). Problemy Tuberkuleza (5): 18-20, 1993.

Tate E. The clinical challenge of progressive myoclonus epilepsy. Nurse Practitioner 18(5): 25-8, May 1993.

Trofimov SS etal. [Piracetam as a corrector of long-term learning disorders caused by prenatal alcohol exposure: the significance of the length of therapy]. Biulleten Eksperimentalnoi Biologii i Meditsiny121(4): 435-7, April 1996.

'I'rofimov SS etal. (Behavior disorders in rats exposed to intrauterine hypoxia, and their correction by postnatal treatment with piracetam. Biulleten Eksperimentalnoi Biologii i Meditsiny 115 (1) 43-5, January 1993.

Tsorin IB, Kazanova GV and Chichkanov GG. [The long-term use of antihypoxants in myocardial infarct in rats: their effect on the hemodynamics and contractile function of the heart]. Eksperimentalnaia i Klinicheskaia Farmakologiia 56(3): 25-7, May-June 1993.

Van Vleymen B and Van Zandijcke M. Piracetam in the treatment of myoclonus: an overview. Acta Neurologica Belgica 96(4): 270-80, December 1996.

Vernon MW and Sorkin EM. Piracetam: An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs & Aging l(l): 17-35, 1991.

6) References; Breastfeeding A Baby with DS; La Leche League

Aumonier, M. and Cunningham, C. Breast-feeding in infants with Down’s Syndrome. Child Care Health Development 1983; 9:247-55.

Broad, F. and Duganzich, D. The effects of infant feeding, birth order, occupation and socio-economic status on speech in six-year-old children. NZ Med J 1983; 96:483-86.

Meier, P. Bottle and breast-feeding: effects on transcutaneous oxygen pressure and temperature in small preterm infants. Nurs Res 1988; 37:36-41.

Page lvi

Mohrbacher, N. and Stock, J. The Breastfeeding Answer Book. Revised Edition. Schaumburg, IL: LLLI, 1997.

Lawrence, R. Breastfeeding: A Guide for the Medical Profession. 4^th ed. St. Louis: Mosby, 1994, p. 443-45.

Riordan, J. and Auerbach K. Breastfeeding and Human Lactation. Boston and London: Jones and Bartlett, 1993, p. 490-91.

Timko, S. etal. Breastfeeding the baby with Down Syndrome. Unit 9, La Leche League International Lactation Consultant Series. Wayne, NJ: Avery Publishing, 1986.

7) References; Sensory Integration; Stephens

Ayers, a. Jean. Sensory Integration and the Child. Los Angeles: Western Psychological Services. 1994. DeGangi, Georgia A. etal. Infant/Toddler Symptom Checklist: A Screening Tool for Parents. Tucson, AR: Therapy Skill Builders, 1995. (1-800-0763-2306)

Sensory Integration International, 1602 Cabrillo Avenue, Torance, CA 90501, (310) 320-9986. (A non-profit organization dedicated to networking and providing information about sensory integration.)

Trott, Maryann Colby etal. SenseAbilities: Understanding Sensory Integration. Tucson, AR: Therapy Skill Builders, 1993.

8) References; Parent’s Guide to Choosing Physician; Ripley & NICHCY

Hickson, G. B., Stewart, D. W., Altemeier, W. A., & Perrin, J. M. (1988). First step in obtaining child health care: Selecting a physician. Pediatrics, 81, 333-338.

10) References; Diagnosis of Autism in Children with DS; Vatter

Bregman, J. D., & Volkmer, F. R. (1988). "Autistic social dysfunction and Down's syndrome," Journal of the American Academy of Child and Adolescent Psychiatry, 27, 440-441.

Coleman, M. (1986). "Down's Syndrome children with autistic features," Down's Syndrome: Papers and Abstracts for Professionals, 1986, 9 ,1-2.

Coleman, M. & Rogers, P. T. (1992). "Medical Care in Down Syndrome: A Preventive Medicine Approach," New York, Marcel Dekker, Inc., pp 208-211.

Collacott, R., Cooper, S., & McGrother, C. (1992). "Differential rates of psychiatric disorders in adults with Down syndrome compared with other mentally handicapped adults," British Journal of Psychiatry, 161, 671-674.

Gath, A. & Gumley, D. (1986). "Behavior problems in retarded children with special reference to Down syndrome," British Journal of Psychiatry, 149, 151-156.

Gillberg, C., Persson, E., Grufman, N., & Themner, U. (1986). "Psychiatric disorders in mildly and severely mentally retarded urban children and adolescents: epidemiological aspects," British Journal of Psychiatry, 149,68-74.

Ghaziuddin, M., Tsai, L., & Ghaziuddin, N. (1992). "Autism in Down's syndrome; presentation and diagnosis," Journal of Intellectual Disability Research, 36, 449-456.

Ghazziudden, M. (1997). "Autism in Down's syndrome: Family history correlates" Journal of Intellectual Disability Research, 41 part1, 87-91.

Page lvii

Howlin, P., Wing, L., & Gould, J. (1995). "The recognition of autism in children with Down's syndrome— implications for intervention and some speculations about pathology," Developmental Medicine and Child Neurology, 37, 406-413.

Knott, F. et. al. (1996). "Sibling interaction of chidren with learning disabilities: A comparison of autism and Down syndrome," Journal of Child Psychology and Psychiatry, 36(6), 965-976.

Loveland, K. A., & Kelley, M. L. (1991). "Development of adaptive behavior in preschoolers with autism or Down syndrome," American Journal on Mental Retardation, 96(1), 13-20.

Loveland, K. A., & Kelley, M. L. (1988). "Development of adaptive behavior in adolescents and young adults with autism and Down syndrome," American Journal on Mental Retardation, 93(1), 84-92.

Lund, J. (1988). "Psychiatric aspects of Down syndrome," Acta Psychiactrica Scandinavia, 78, 369-374.

Maltz, A., & Schopler, E. (1979) "Down's Syndrome and early infantile autism: Diagnostic confusion?" Journal of Autism and Developmental Disorders, 9, No.4, 453-456.

Myers, B. A. & Pueschel, S. M. (1991). "Psychiatric Disorders in Persons with Down Syndrome," The Journal of Nervous and Mental Disease, 179, 609-613.

Pary, R. J. (1997). "Comorbidity of Down syndrome and autism," The Habilitative Mental Healthcare Newsletter, 16(1).

Turk, J. (1992). "Children with Down's syndrome and Fragile X syndrome: a comparison study," Society for Study of Behavioral Phenotypes: 2nd Symposium Abstracts, Oxford:SSSP

Vatter, G. (1997). "Billy, A Family's Experience with a Multiply Disabled Child," self published.

Wakabayashi, S. (1979). "A case of infantile autism associated with Down's syndrome," Journal of Autism and Developmental Disorders, 9, 31-36.

Wing L. & Gould, J. (1979). "Severe impairment of social interaction and associated abnormalities in children; epidemiology and classification," Journal of Autism and Developmental Disorders, 9, 11-29.

Yirmiya, N. et. al. (1996). "Theory of mind abilities in individuals with autism, Down syndrome, and mental retardation of unknown etiology: The role of age and intelligence," Journal of Child Psycology and Psychiatry, 37(8), 1003-1014.

11) References; Celiac-An Introduction; Adams

1.New England Journal of Medicine, May 2, 1996 -- Volume 334, Number 18, "The Many Faces of Celiac Disease" by Charles H. Halsted, M.D.
2.Gastroenterology, April, 1996 "First Epidemiological Study of Gluten Intolerance in the United States." By Karoly Horvath, M.D., Ph.D., et. al..
3.Goggins, et. al. "Celiac Disease and Other Nutrient Related Injuries to the Gastrointestinal Tract" The American Journal of Gastroenterology. Vol. 89, No. 8, pages S2 - S13, 1994.
4.United States Census Bureau, 1990.

12) References; Broad Overview of Celiac Disease; Gislason
1. Unsworth, D.J., et. al., IgA Anti-Gliadin Antibodies in Celiac disease, Clin Exp Immunol. 1981: 46:286-93. Keiffer M, et. al., Wheat Gliadin Fractions and Other Cereal Antigens Reactive with Antibodies in the Sera of Celiac Patients, Clin Exp Immunol. 1982;50:651-60.

2. Bell L., Hoffer M., Recommendations for Foods of Questionable Acceptance for Patients with Celiac Disease, J.Can. Dietetic Ass'n: 1981; 42:2; 143-15

Page lviii

3. Bjarnson, I., et. al., Intestinal Permeability Defect in Celiac Disease, Lancet. 1983 1284-85

4. O'Farrelly, et. al., Alpha-Gliadin Antibody Levels: A Serological Test for Celiac Disease, 1983 Lancet; 286:2007-2010

5. Waller, S.L., Misiewicsz: Lancet 1969 ii: 753-6, Prognosis in Irritable Bowel Syndrome

6. Food for Celiacs; Campbell, J.A. : Journal of the Canadian Dietetic Ass'n., Jan '82 ; 43:1; 20-24; Gluten Free Cookbook: Leicht, L., RR#1 Box 54, Pender Island B.C. VON 2MO; Club House Foods 316 Rectory St. PO Box 788 London Ont. N6A 4Z2

7. Tassajara Cooking; 1973 Zen Centre; San Francisco; Shambala Publications, Inc. Boulder, CO

13) References: Dental Care for the Patient with Down Syndrome; Pilcher
Barnett M.L., Friedman D., & Kastner T. (1988). The prevalence of mitral valve prolapse in patients with Down syndrome: Implications for dental management. Oral Surgery Oral Medicine Oral Pathology, 66, 445-7.

Barnett M.L., Press, K.P., Friedman, D., & Sonnenburg, E.M. (1986). The prevalence of periodontitis and dental caries in a Down syndrome population. Journal of Periodontology, 57, 288-93.

Bloch K., Witztum, A., Wieser, H.G., Schmid, S., & Russi, E. (1990). Obstructive sleep apnea in a child with trisomy 21. Monatsschr ift Kinderheilkunde, 138, 817-22.

Devenny, D.A., Hill, A.L., Patxot, O., Silverman, W.P., & Wisniewski, K.E. (1992). Ageing in higher functioning adults with Down syndrome: an interim report in a longitudinal study. Journal of Intellectual Disabilities Research, 36, 241-50.

Fischer-Brandeis, H. (1989). The time of eruption of the milk teeth in Down's syndrome. Fortschritte derKeiferothopadie, 50, 144-51.

Margar-Bacal, F., Witzel, M.A., & Munro, I.R. (1987). Speech intelligibility after partial glossectomy in children with Down's syndrome. Plastic and Reconstructive Surgery, 79, 44-9.

Morinushi, T., Lopatin, D.E., & Tanaka, H. (1995). The relationship between dental caries in the primary dentition and anti S. Mutans serum antibodies in children with Down's syndrome. Journal of Clinical Pediatric Dentistry, 19, 279-83.

Müssig, D., Hickel, R., & Zschiesche, S. (1990). The eruption of decidious teeth in children with various forms of Down's syndrome and congenital heart defects. Deutche Zahnarzteblatt, 45, 157-9.

Ondarza, A., Jara, L., Bertonati, M.I., & Blanco, R. (1995). Tooth malalignments in Chilean children with Down's syndrome. Cleft Palate Craniofacial Journal, 32, 188-93.

Phillips, D.E., & Rogers, J.H. (1988). Down's syndrome with lingual tonsil hypertrophy producing sleep apnea. Journal of Laryngology & Otolaryngology, 102, 1054-5.

Reuland-Bosma, W. (1990). Periodontal disease in Down's syndrome. Ned Jijdscrift voor Tandheelkkunde, 97, 468-71.

Shapira, J., Stabholtz, A., Schurr, D., Sela, M.N., & Mann, J. (1991). Caries level, Streptococcus mutans counts, salivary pH and periodontal treatment needs of adult Down syndrome patients. Special Care Dentist, 11, 248-51.

Page lix

Shaw, L., & Saxby, M.S. (1986). Periodontal destruction in Down's syndrome and in juvenile periodontitis; how close a similarity? Journal of Periodontology, 57, 709-13.

Sigal, M.J., & Levine, N. (1993). Down's syndrome and Alzheimer's disease. Journal of the Canadian Dental Association, 59, 823-29.

Silverman, M. (1988). Airway obstruction and sleep disruption in Down's syndrome. British Medical Journal, 296, 1618-9.

Sohoel, P.D., Johannessen, A.C., Kristofferson, T., Haugstvedt, Y., & Nilsen, R. (1992). In situ characteristics of mononuclear cells in marginal periodontitis of patients with Down's syndrome. Acta Odontologica Scandinavia, 50, 141-9.

Sohoel, P.D., Johannessen, A.C., Kristofferson, T., & Nilsen, R. (1995). Expression of HLA Class II antigens in marginal periodontitis of patients with Down's syndrome. European Journal of Oral Science, 103, 207-13.

Southern Association of Institutional Dentists (1994). Southern Assoc of Institutional Dentists Self-study Course: Module 3 Down syndrome.

Stabholtz, A., Shapira, J., Shur, D., Friedman, M., Guberman, R., & Selam M.N. (1991). Local application of sustained-release delivery system of chlorhexedine in Down's syndrome population. Clinical Preventive Dentistry, 13, 9-14.

Starmans J.L., & Bloem, J.J. (1991). Tongue reduction in children with Down's syndrome, a functional operation. Nederlands Tijdschrift Voor Geneeskunde, 135, 1963-6.

Stebbens, V.A., Dennis, J., Samuels, M.P., Croft, C.B., & Southhall, D.P. (1991). Sleep related upper airway obstruction in a cohort with Down's syndrome. Archives of the Disabled Child, 66, 1333-8.

Vicari. S., & Caltagirone, C. (1990). Alzheimer's disease and Down syndrome: a review. Rivista Neurologica, 60, 151-9.

Vittek. J., Winik, S., Winik, A., Sioris, C., Tarangelo, A.M., & Chou, M. (1994). Analysis of orthodontic anomalies in mentally retarded developmentally disabled persons. Special Care Dentist, 14, 198-202. Yavuzyilmaz, E., Ersoy, F., Sanal, O., Tezcan, I., & Ercal, D. (1993). Neutrophil chemotaxis and periodontal status in Down syndrome patients. Journal of Nihon University School of Dentistry, 35, 91-5.

14) References; Introduction to Hirschsprung Disease; Bishop
1) Title: Hirschsprung disease: a genetic study Journal: Clin Genet Date of Pub: 1985 Dec Author: Garver KL, Law JC, Garver B Issue/Part/Supplement: 6 Volume: 28 Pagination: 503-8

2) Title: The influence of trisomy 21 on outcome in children with Hirschsprung's disease Journal: J Pediatr Surg Date of Pub: 1994 Jun Author: Quinn FM; Surana R; Puri P Issue/Part/Supplement: 6 Volume: 29 Pagination: 781-3

3) Title: An epidemiological study of Hirschsprung's disease Journal: Int J Epidemiol Date of Pub: 1984 Dec Author: Goldberg EL Issue/Part/Supplement: 4 Volume: 13 Pagination: 479-85

4) Title: Identity-by-descent and association mapping of a recessive gene for Hirschsprung disease on human chromosome 13q22 Journal: Hum Mol Genet Date of Pub: 1994 Aug Author: Puffenberger EG, Kauffman ER, Bolk S, Matise TC, Washington SS, Angrist M, Weissenbach J, Garver KL, Mascari M, Ladda R, etal Issue/Part/Supplement: 8 Volume: 3 Pagination: 1217-25

5) Title: The genetics of Hirschsprung's disease: evidence for heterogeneous etiology and a study of sixty-three families. Journal: New Eng. J. Med. Date of Pub: 1967 Author: Passarge, E. Issue/Part/Supplement:

Page lx

276 Pagination: 138-143.

6) Title: Gastrointestinal function after surgical correction of Hirschsprung's disease: long-term follow-up in 135 patients. Journal: J Pediatr Surg Date of Pub: 1995 May Author: Marty TL, Seo T, Matlak ME, Sullivan JJ, Black RE, Johnson DG. Issue/Part/Supplement: 30(5) Pagination: 655-8.